---
schema_version: "secwatch.filing_event.v1"
accession: "0000929638-25-002215"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2025-06-10T23:59:59+00:00"
generated_at: "2026-05-19T16:17:53.722455+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Shareholders approve 2025 Employee Stock Purchase Plan; directors elected

## Summary
- Shareholders approved the 2025 ESPP reserving 2,000,000 common shares for issuance.
- Directors Gerald Brunk and Dr. Richard Glickman were elected with 30.5M and 26.3M for votes respectively.
- ESPP effective June 10, 2025, allows eligible employees to purchase shares via payroll deductions.
- Auditor appointment ratified with 38,101,229 votes in favor.
- ESPP intended to qualify under Code Section 423; 74.6% of outstanding shares voted at the meeting.

## SEC filing metadata
- accession: 0000929638-25-002215
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2025-06-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000092963825002215/0000929638-25-002215-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000092963825002215/a8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000929638-25-002215
- JSON: https://secwatch.observer/filing/0000929638-25-002215.json
- Plain text: https://secwatch.observer/filing/0000929638-25-002215.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.